LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled® budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo.
